Despite Dilution, Aratana Therapeutics Can Keep Climbing

Aratana Therapeutics recently announced conditional approval by the USDA of its lymphoma treatment for dogs, a big potential revenue driver.

Jan 30, 2014 at 6:30PM

 

Aratana Therapeutics (NASDAQ:PETX), one of the best-performing biotech IPOs last year, rallied on January 28 after the company announced that the USDA had granted a conditional approval for AT-005, Aratana's T-cell lymphoma treatment for dogs. This is the second of Aratana's lymphoma canine treatments to be approved, following the conditional approval of the B-cell lymphoma drug AT-004 in 2012.

AT-005 is highly significant for Aratana, since it represents the company's first internal commercial opportunity. Its predecessor, AT-004, was licensed to Novartis Animal Health for commercialization in the United States and Canada.

PETX Chart

Source: YCharts.

Is this recent bullish development a good reason to invest in Aratana, which has already rallied more than 130% since its market debut? Let's take a look at three key factors to consider.

1. An exclusive bet on pet health products
What makes Aratana an appealing investment is that there aren't many companies like it.

Other animal health companies, such as Zoetis, focus on both farm animals and companion animals. The same can be said of the other leaders in the field -- Novartis Animal Health, Merck (NYSE:MRK) Animal Health, Eli Lilly's Elanco, and Sanofi's (NYSE:SNY) Merial.

While those companies are affected by both pet and livestock issues, Aratana is a pure bet on the growing demand for veterinary pharmaceuticals. According to the company, annual spending by U.S. pet owners has surged 212% from $17 billion in 1994 to $53 billion in 2013.

Market trends reflect Aratana's forecasts. Last quarter, Zoetis, the largest pure animal health play on the market, reported that sales of its companion animal products rose across all four of its geographical regions. Sales were particularly strong in the U.S. and in Canada/Latin America, where revenue respectively rose 10% and 19% from the prior-year quarter.

However, when we compare Zoetis to Sanofi, Merck, and Lilly's animal health units, we see some glaring discrepancies:

 

Animal Health Segment Revenue (most recent quarter)

YOY Growth

Zoetis

$1.1 billion

8%

Sanofi (Merial)

$626 million

(6.4%)

Merck (Merck Animal Health)

$800 million

(2%)

Eli Lilly (Elanco)

$530 million

10.6%

Source: Quarterly earnings reports.

Sanofi and Merck's negative growth shouldn't worry Aratana investors, however. Sanofi posted negative sales growth due to generic competition for its Frontline flea and tick control treatment -- a market that Aratana is not involved in. Meanwhile, Merck's animal health segment stumbled after its non-hormone growth promoter Zilmax was banned by major customers after it was found to cause lameness in cattle. Again, Aratana is not exposed at all to the livestock market, which makes it a more attractive, higher growth animal health play than any of the above companies.

2. An attractive pipeline of better treatments
Last December, Aratana announced that it had met all of its 2013 milestone developments. Here were the key highlights:

Drug

Indication

Update

Anticipated Approval Date

AT-001

osteoarthritis

61.6% success rate vs. 42.2% for the placebo group

2016

AT-002

appetite stimulant

Initiated a new study with 150 dogs

2016

AT-003

post-operative pain

Plans to start a field study for dogs

2016

AT-004

T-cell lymphoma

Conditional USDA approval, commercialized by Novartis

--

AT-005

T-cell lymphoma

Conditional USDA approval, will be commercialized by Aratana

--

Source: Company press releases.

AT-001 and AT-003 could represent substantial improvements over the broad spectrum of NSAIDs (non-steroidal anti-inflammatory drugs) which are currently used to treat pain and inflammation in dogs.

AT-002 could compare favorably to the current treatments for inappetance, which surprisingly include human allergy drugs like Johnson & Johnson's Benadryl (diphenhydramine) or cyproheptadine. In addition, AT-001, AT-002, and AT-003 are all being tested for cats as well.

Meanwhile, both AT-004 and AT-005, which Aratana gained via its $30 million acquisition of Vet Therapeutics in October, have huge market potential, since lymphoma is the most common blood cancer in dogs and accounts for roughly 6% of all canine cancers. The most common treatment today is chemotherapy, which can cost between $3,500 to $10,000 per dog. Therefore, AT-004 and AT-005, which are both monoclonal antibodies, have game-changing potential as two of the first targeted treatments for dog lymphoma. Aratana expects a full approval license for AT-005 in 2015, make the drug Aratana's first pillar of real revenue growth.

Earlier this month, Aratana also acquired Okapi Sciences for its rich portfolio of feline antiviral and immunodeficiency drugs, and oncology drugs for both cats and dogs. If Okapi's lead drug candidate, a treatment for ocular disease caused by feline herpes, is approved, Aratana intends to commercialize the product in several territories under a current commercialization agreement with Novartis Animal Health.

3. A proposed public offering could mean lower prices ahead
Although Aratana has a robust pipeline, it finished last quarter with only $52.3 million in cash and equivalents. Meanwhile, it has a negative operating cash flow over the past 12 months of $13.8 million, $4.9 million in debt, and no meaningful sources of revenue.

Therefore, to fund upcoming studies, Aratana proposed a public offering of 6.5 million shares of common stock, priced at $19.00, on January 29. Aratana will sell 5 million shares, and two other major stockholders will sell 1.5 million shares. Considering that there are only 23.8 million outstanding shares on the market, that new offering will significantly dilute existing shares.

The company intends to raise $95 million from the sale, which will help cover its acquisitions of Vet Therapeutics and Okapi Sciences and upcoming trials. However, this means that lower prices could be on the horizon, which could be the ideal time for new investors to pick up some shares.

The Foolish takeaway
In closing, Aratana is a speculative, pre-revenue biotech company fully dedicated to the growing market for veterinary therapeutics. Aratana's robust pipeline and ambitious inorganic growth all indicate there is plenty of room for growth, but investors should remember that until the company actually generates revenue, no one can be sure what the stock is really worth. Aratana has had a spectacular triple-digit run over the past 12 months, and a new public offering is right around the corner, so lower prices could be ahead. Therefore, this is definitely a stock better suited for investors who can stomach the near-term volatility.

These other biotech stocks are worth watching
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies set to profit from this emerging drug class. Click here to get your copy today.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers